Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Study objective: To investigate the potential anti-proteinuric and renoprotective efficacy of
aliskiren in addition to losartan in patients at risk of developing end-stage renal disease
(ESRD)
Methods: This will be a randomized, double-blind study in which proteinuric, non-diabetic
patients with chronic kidney disease (CKD) will be assigned in a 1:1 ratio to one of the
following treatment groups for 3 years:
- Group A: Losartan (Control arm: conventional treatment)*
- Group B: Aliskiren plus Losartan (Intervention arm)*
- With optional addition of other anti-hypertensive agents to achieve an optimal
target blood pressure of <130/80 mmHg.